Characterization of tumor heterogeneity at the sequence level presents new challenges and opportunities for targeted therapies.
References
Nowell, P.C. Science 194, 23–28 (1976).
Hou, Y. et al. Cell 148, 873–885 (2012).
Xu, X. et al. Cell 148, 886–895 (2012).
Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).
Navin, N. et al. Nature 472, 90–94 (2011).
Anderson, K. et al. Nature 469, 356–361 (2011).
Shah, S.P. et al. Nature 461, 809–813 (2009).
Yachida, S. et al. Nature 467, 1114–1117 (2010).
Campbell, P.J. et al. Nature 467, 1109–1113 (2010).
Shah, S.P. et al. Nature 10.1038/nature10933 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Caldas, C. Cancer sequencing unravels clonal evolution. Nat Biotechnol 30, 408–410 (2012). https://doi.org/10.1038/nbt.2213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2213
- Springer Nature America, Inc.
This article is cited by
-
Evolving copy number gains promote tumor expansion and bolster mutational diversification
Nature Communications (2024)
-
De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution
Scientific Reports (2019)
-
Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes
BMC Cancer (2015)
-
Comparison of variations detection between whole-genome amplification methods used in single-cell resequencing
GigaScience (2015)
-
Bone specific immunity and its impact on metastasis
BoneKEy Reports (2015)